Possible Interaction: Tranylcypromine and Tretinoin

“Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells …-SCID γ (with interleukin-2 (IL-2) receptor γ chain deficiency) mice also revealed the ATRA … TCP drug combination to have a potent anti-leukemic effect … was superior to treatment with either drug alone.”

“Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells.”

“PURPOSE In preclinical studies, the LSD1 inhibitor tranylcypromine (TCP) combined with all-trans retinoic acid (ATRA) induces differentiation and impairs survival of myeloid blasts in non-APL acute myeloid leukemia (AML).”

“Purpose: In preclinical studies, the lysine-specific histone demethylase 1A (LSD1) inhibitor tranylcypromine (TCP) combined with all-trans retinoic acid (ATRA) induces differentiation and impairs survival of myeloid blasts in non-acute promyelocytic leukemia acute myeloid leukemia (AML).”

“Further in vitro studies showed that the combination of ATRA and TCP was more effective at reducing the survival and proliferation of HL-60 cells than treatment with single agents.”

“Next, the authors studied the effects of ATRA and TCP on gene expression, and showed that the drug combination upregulated the expression of genes that were associated with myeloid differentiation or apoptosis.”